Endothelial chemokines in autoimmune disease

Current Pharmaceutical Design

Volumn 10, Issue 2, 2004, Pages 145-154

  Christopherson II, Kent W ^a   Hromas, Robert A ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

Allograft rejection; Atopic dermatitis; Autoimmune disease; Chemokine; Chemokine receptor; Graft virus host disease; Lichen planus; Multiple sclerosis; Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; 1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); ANTIRHEUMATIC AGENT; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; G PROTEIN COUPLED RECEPTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 17; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; N [3 (AMINOSULFONYL) 4 CHLORO 2 HYDROXYPHENYL] N' [2,3 DICHLOROPHENYL]UREA; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; RANTES; RECEPTOR BLOCKING AGENT; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG;

ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; DIAGNOSTIC VALUE; DRUG MECHANISM; ENDOTHELIUM; ENDOTHELIUM CELL; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; LICHEN PLANUS; MOLECULAR WEIGHT; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SYMPTOMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOIMMUNE DISEASES; CHEMOKINES; ENDOTHELIUM, VASCULAR; HUMANS; LYMPHOID TISSUE; RECEPTORS, CHEMOKINE;

EID: 0346025497     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043453405     Document Type: Review

References (105)

1. Oppenheim JJ. Overview of chemokines. Adv Exp Med Biol 1993; 351: 183-6.
2. Schall TJ, Bacon KB. Chemokines, leukocyte trafficking, and inflammation. Curr Opin Immunol 1994; 6(6): 865-73.
3. Kim CH, Broxmeyer HE. Chemokines: signal lamps for trafficking of T and B cells for development and effector function. J Leukoc Biol 1999; 65(1): 6-15.
4. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18: 217-42.
5. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998; 392(6676): 565-8.
6. Locati M, Murphy PM. Chemokines and chemokine receptors: biology and clinical relevance in inflammation and AIDS. Annu Rev Med 1999; 50: 425-40.
7. Feng L. Role of chemokines in inflammation and immunoregulation. Immunol Res 2000; 21(2-3): 203-10.
8. Furie MB, Randolph GJ. Chemokines and tissue injury. Am J Pathol 1995; 146(6): 1287-301.
9. Baggiolini M, Dahinden CA. CC chemokines in allergic inflammation. Immunol Today 1994; 15(3): 127-33.
10. Strieter RM, Standiford TJ, Huffnagle GB, Colletti LM, Lukacs NW, Kunkel SL. "The good, the bad, and the ugly." The role of chemokines in models of human disease. J Immunol 1996; 156(10): 3583-6.
11. Hosaka S, Akahoshi T, Wada C, Kondo H. Expression of the chemokine superfamily in rheumatoid arthritis. Clin Exp Immunol 1994; 97(3): 451-7.
12. Kasama T, Strieter RM, Lukacs NW, Lincoln PM, Burdick MD, Kunkel SL. Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis. J Clin Invest 1995; 95(6): 2868-76.
13. Kukielka GL, Youker KA, Michael LH, Kumar AG, Ballantyne CM, Smith CW, et al. Role of early reperfusion in the induction of adhesion molecules and cytokines in previously ischemic myocardium. Mol Cell Biochem 1995; 147(1-2): 5-12.
14. Massey KD, Strieter RM, Kunkel SL, Danforth JM, Standiford TJ. Cardiac myocytes release leukocyte-stimulating factors. Am J Physiol 1995; 269(3 Pt 2): H980-7.
15. Clark-Lewis I, Kim KS, Rajarathnam K, Gong JH, Dewald B, Moser B, et al. Structure-activity relationships of chemokines. J Leukoc Biol 1995; 57(5): 703-11.
16. Pal R, Garzino-Demo A, Markham PD, Burns J, Brown M, Gallo RC, et al. Inhibition of HIV-1 infection by the beta-chemokine MDC. Science 1997; 278(5338): 695-8.
17. Struyf S, Proost P, Sozzani S, Mantovani A, Wuyts A, De Clercq E, et al. Enhanced anti-HIV-1 activity and altered chemotactic potency of NH2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor. J Immunol 1998; 161(6): 2672-5.
18. Struyf S, De Meester I, Scharpe S, Lenaerts JP, Menten P, Wang JM, et al. Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor. Eur J Immunol 1998; 28(4): 1262-71.
19. Wuyts A, Govaerts C, Struyf S, Lenaerts JP, Put W, Conings R, et al. Isolation of the CXC chemokines ENA-78, GRO alpha and GRO gamma from tumor cells and leukocytes reveals NH2-terminal heterogeneity. Functional comparison of different natural isoforms. Eur J Biochem 1999; 260(2): 421-9.
20. Tensen CP, Flier J, Van Der Raaij-Helmer EM, Sampat-Sardjoepersad S, Van Der Schors RC, Leurs R, et al. Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). J Invest Dermatol 1999; 112(5): 716-22.
21. Noso N, Bartels J, Mallet AI, Mochizuki M, Christophers E, Schroder JM. Delayed production of biologically active O-glycosylated forms of human eotaxin by tumor-necrosis-factor-alpha-stimulated dermal fibroblasts. Eur J Biochem 1998; 253(1): 114-22.
22. Vulcano M, Albanesi C, Stoppacciaro A, Bagnati R, D'Amico G, Struyf S, et al. Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo. Eur J Immunol 2001; 31(3): 812-22.
23. Katz A, Wu D, Simon MI. Subunits beta gamma of heterotrimeric G protein activate beta 2 isoform of phospholipase C. Nature 1992; 360(6405): 686-9.
24. Wu D, LaRosa GJ, Simon MI. G protein-coupled signal transduction pathways for interleukin-8. Science 1993; 261(5117): 101-3.
25. Turner L, Ward SG, Westwick J. RANTES-activated human T lymphocytes. A role for phosphoinositide 3-kinase. J Immunol 1995; 155(5): 2437-44.
26. Leopoldt D, Hanck T, Exner T, Maier U, Wetzker R, Nurnberg B. Gbetagamma stimulates phosphoinositide 3-kinase-gamma by direct interaction with two domains of the catalytic p110 subunit. J Biol Chem 1998; 273(12): 7024-9.
27. Ganju RK, Brubaker SA, Meyer J, Dutt P, Yang Y, Qin S, et al. The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem 1998; 273(36): 23169-75.
28. Majka M, Ratajczak J, Kowalska MA, Ratajczak MZ. Binding of stromal derived factor-1alpha (SDF-1alpha) to CXCR4 chemokine receptor in normal human megakaryoblasts but not in platelets induces phosphorylation of mitogen-activated protein kinase p42/44 (MAPK), ELK-1 transcription factor and serine/threonine kinase AKT. Eur J Haematol 2000; 64(3): 164-72.
29. Wang JF, Park IW, Groopman JE. Stromal cell-derived factor-1alpha stimulates tyrosine phosphorylation of multiple focal adhesion proteins and induces migration of hematopoietic progenitor cells: roles of phosphoinositide-3 kinase and protein kinase C. Blood 2000; 95(8): 2505-13.
30. Li Z, Jiang H, Xie W, Zhang Z, Smrcka AV, Wu D. Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. Science 2000; 287(5455): 1046-9.
31. Daaka Y, Luttrell LM, Ahn S, Della Rocca GJ, Ferguson SS, Caron MG, et al. Essential role for G protein-coupled receptor endocytosis in the activation of mitogen-activated protein kinase. J Biol Chem 1998; 273(2): 685-8.
32. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12(2): 121-7.
33. International Union of Immunological Societies/World Health Organization Subcommittee on chemokine nomenclature. Chemokine/chemokine receptor nomenclature. J Leukoc Biol 2001; 70(3): 465-6.
34. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000; 52(1): 145-76.
35. Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest 1989; 84(4): 1045-9.
36. Dewald B, Moser B, Barella L, Schumacher C, Baggiolini M, Clark-Lewis I. IP-10, a gamma-interferon-inducible protein related to interleukin-8, lacks neutrophil activating properties. Immunol Lett 1992; 32(1): 81-4.
37. Forster R, Mattis AE, Kremmer E, Wolf E, Brem G, Lipp M. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 1996; 87(6): 1037-47.
38. Proost P, Wuyts A, Van Damme J. Human monocyte chemotactic proteins-2 and -3: structural and functional comparison with MCP-1. J Leukoc Biol 1996; 59(1): 67-74.
39. Gerard C, Frossard JL, Bhatia M, Saluja A, Gerard NP, Lu B, et al. Targeted disruption of the beta-chemokine receptor CCR1 protects against pancreatitis-associated lung injury. J Clin Invest 1997; 100(8): 2022-7.
40. Hieshima K, Imai T, Opdenakker G, Van Damme J, Kusuda J, Tei H, et al. Molecular cloning of a novel human CC chemokine liver and activation-regulated chemokine (LARC) expressed in liver. Chemotactic activity for lymphocytes and gene localization on chromosome 2. J Biol Chem 1997; 272(9): 5846-53.
41. Yoshida R, Imai T, Hieshima K, Kusuda J, Baba M, Kitaura M, et al. Molecular cloning of a novel human CC chemokine EBI1-ligand chemokine that is a specific functional ligand for EBI1, CCR7. J Biol Chem 1997; 272(21): 13803-9.
42. Braun SE, Chen K, Foster RG, Kim CH, Hromas R, Kaplan MH, et al. The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J Immunol 2000; 164(8): 4025-31.
43. Hedrick JA, Zlotnik A. Identification and characterization of a novel beta chemokine containing six conserved cysteines. J Immunol 1997; 159(4): 1589-93.
44. Nagira M, Imai T, Hieshima K, Kusuda J, Ridanpaa M, Takagi S, et al. Molecular cloning of a novel human CC chemokine secondary lymphoid-tissue chemokine that is a potent chemoattractant for lymphocytes and mapped to chromosome 9p13. J Biol Chem 1997; 272(31): 19518-24.
45. Hromas R, Kim CH, Klemsz M, Krathwohl M, Fife K, Cooper S, et al. Isolation and characterization of Exodus-2, a novel C-C chemokine with a unique 37-amino acid carboxyl-terminal extension. J Immunol 1997; 159(6): 2554-8.
46. Campbell JJ, Butcher EC. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr Opin Immunol 2000; 12(3): 336-41.
47. Hedrick JA, Zlotnik A. Chemokines and chemokine receptors in T-cell development. Chem Immunol 1999; 72: 57-68.
48. Christopherson KW 2nd, Campbell JJ, Hromas RA. Transgenic overexpression of the CC chemokine CCL21 disrupts T-cell migration. Blood 2001; 98(13): 3562-8.
49. Rossi DL, Vicari AP, Franz-Bacon K, McClanahan TK, Zlotnik A. Identification through bioinformatics of two new macrophage proinflammatory human chemokines: MIP-3alpha and MIP-3beta. J Immunol 1997; 158(3): 1033-6.
50. Hromas R, Gray PW, Chantry D, Godiska R, Krathwohl M, Fife K, et al. Cloning and characterization of exodus, a novel beta-chemokine. Blood 1997; 89(9): 3315-22.
51. Sharma S, Stolina M, Luo J, Strieter RM, Burdick M, Zhu LX, et al. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol 2000; 164(9): 4558-63.
52. Nomura T, Hasegawa H. Chemokines and anti-cancer immunotherapy: anti-tumor effect of EBI1-ligand chemokine (ELC) and secondary lymphoid tissue chemokine (SLC). Anticancer Res 2000; 20(6A): 4073-80.
53. Murphy PM. Viral exploitation and subversion of the immune system through chemokine mimicry. Nat Immunol 2001; 2(2): 116-22.
54. Krathwohl MD, Hromas R, Brown DR, Broxmeyer HE, Fife KH. Functional characterization of the C - C chemokine-like molecules encoded by molluscum contagiosum virus types 1 and 2. Proc Natl Acad Sci USA 1997; 94(18): 9875-80.
55. Gallo RC. The enigmas of Kaposi's sarcoma. Science 1998; 282(5395): 1837-9.
56. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001; 2(2): 108-15.
57. Keane MP, Strieter RM. Chemokine signaling in inflammation. Crit Care Med 2000; 28(4 Suppl): N13-26.
58. Hjelmstrom P, Fjell J, Nakagawa T, Sacca R, Cuff CA, Ruddle NH. Lymphoid tissue homing chemokines are expressed in chronic inflammation. Am J Pathol 2000; 156(4): 1133-8.
59. Fife BT, Huffnagle GB, Kuziel WA, Karpus WJ. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J Exp Med 2000; 192(6): 899-905.
60. Starnes T, Robertson MJ, Sledge G, Kelich S, Nakshatri H, Broxmeyer HE, et al. Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production. J Immunol 2001; 167(8): 4137-40.
61. Starnes T, Broxmeyer HE, Robertson MJ, Hromas R. Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis. J Immunol 2002; 169(2): 642-6.
62. Mangge H, Vojinovic J, Schauenstein K. Do chemokines spark autoimmunity in juvenile and adult rheumatic disease? Immunobiology 2002; 206(4): 459-71.
63. Izikson L, Klein RS, Charo IF, Weiner HL, Luster AD. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med 2000; 192(7): 1075-80.
64. Rottman JB, Slavin AJ, Silva R, Weiner HL, Gerard CG, Hancock WW. Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent. Eur J Immunol 2000; 30(8): 2372-7.
65. Kennedy KJ, Strieter RM, Kunkel SL, Lukacs NW, Karpus WJ. Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1alpha and monocyte chemotactic protein-1. J Neuroimmunol 1998; 92(1-2): 98-108.
66. Sorensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999; 103(6): 807-15.
67. Trebst C, Ransohoff RM. Investigating chemokines and chemokine receptors in patients with multiple sclerosis: opportunities and challenges. Arch Neurol 2001; 58(12): 1975-80.
68. Hancock WW, Lu B, Gao W, Csizmadia V, Faia K, King JA, et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000; 192(10): 1515-20.
69. Nelson PJ, Krensky AM. Chemokines, chemokine receptors, and allograft rejection. Immunity 2001; 14(4): 377-86.
70. Hancock WW, Gao W, Faia KL, Csizmadia V. Chemokines and their receptors in allograft rejection. Curr Opin Immunol 2000; 12(5): 511-6.
71. Wada T, Yokoyama H, Su SB, Mukaida N, Iwano M, Dohi K, et al. Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int 1996; 49(3): 761-7.
72. Kaneko H, Ogasawara H, Naito T, Akimoto H, Lee S, Hishikawa T, et al. Circulating levels of beta-chemokines in systemic lupus erythematosus. J Rheumatol 1999; 26(3): 568-73.
73. Tesch GH, Maifert S, Schwarting A, Rollins BJ, Kelley VR. Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. J Exp Med 1999; 190(12): 1813-24.
74. Campbell JJ, Haraldsen G, Pan J, Rottman J, Qin S, Ponath P, et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 1999; 400(6746): 776-80.
75. Homey B, Alenius H, Muller A, Soto H, Bowman EP, Yuan W, et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med 2002; 8(2): 157-65.
76. Spandau U, Toksoy A, Goebeler M, Brocker EB, Gillitzer R. MIG is a dominant lymphocyte-attractant chemokine in lichen planus lesions. J Invest Dermatol 1998; 111(6): 1003-9.
77. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001; 19(16): 3685-91.
78. Barker JN, Davies SM, DeFor T, Ramsay NK, Weisdorf DJ, Wagner JE. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood 2001; 97(10): 2957-61.
79. Leung W, Ramirez M, Mukherjee G, Perlman EJ, Civin CI. Comparisons of alloreactive potential of clinical hematopoietic grafts. Transplantation 1999; 68(5): 628-35.
80. Murai M, Yoneyama H, Harada A, Yi Z, Vestergaard C, Guo B, et al. Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J Clin Invest 1999; 104(1): 49-57.
81. Serody JS, Burkett SE, Panoskaltsis-Mortari A, Ng-Cashin J, McMahon E, Matsushima GK, et al. T-lymphocyte production of macrophage inflammatory protein-1alpha is critical to the recruitment of CD8(+) T cells to the liver, lung, and spleen during graft-versus-host disease. Blood 2000; 96(9): 2973-80.
82. Christopherson KW 2nd, Hood AF, Travers JB, Ramsey H, Hromas RA. Endothelial induction of the T-cell chemokine CCL21 in T-cell autoimmune diseases. Blood 2003; 101(3): 801-6.
83. Sasaki M, Hasegawa H, Kohno M, Inoue A, Ito MR, Fujita S. Antagonist of secondary lymphoid-tissue chemokine (CCR ligand 21) prevents the development of chronic graft-versus-host disease in mice. J Immunol 2003; 170(1): 588-96.
84. Ajuebor MN, Swain MG, Perretti M. Chemokines as novel therapeutic targets in inflammatory diseases. Biochem Pharmacol 2002; 63(7): 1191-6.
85. Power CA, Proudfoot AE. The chemokine system: novel broad-spectrum therapeutic targets. Curr Opin Pharmacol 2001; 1(4): 417-24.
86. Howard OM, Oppenheim JJ, Wang JM. Chemokines as molecular targets for therapeutic intervention. J Clin Immunol 1999; 19(5): 280-92.
87. Horuk R, Ng HP. Chemokine receptor antagonists. Med Res Rev 2000; 20(2): 155-68.
88. Grainger DJ, Reckless J. Broad-spectrum chemokine inhibitors (BSCIs) and their anti-inflammatory effects in vivo. Biochem Pharmacol 2003; 65(7): 1027-34.
89. Horuk R, Shurey S, Ng HP, May K, Bauman JG, Islam I, et al. CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model. Immunol Lett 2001; 76(3): 193-201.
90. Horuk R, Clayberger C, Krensky AM, Wang Z, Grone HJ, Weber C, et al. A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection. J Biol Chem 2001; 276(6): 4199-204.
91. Grone HJ, Weber C, Weber KS, Grone EF, Rabelink T, Klier CM, et al. Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J 1999; 13(11): 1371-83.
92. Plater-Zyberk C, Hoogewerf AJ, Proudfoot AE, Power CA, Wells TN. Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol Lett 1997; 57(1-3): 117-20.
93. Matsui M, Weaver J, Proudfoot AE, Wujek JR, Wei T, Richer E, et al. Treatment of experimental autoimmune encephalomyelitis with the chemokine receptor antagonist Met-RANTES. J Neuroimmunol 2002; 128(1-2): 16-22.
94. Podolin PL, Bolognese BJ, Foley JJ, Schmidt DB, Buckley PT, Widdowson KL, et al. A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit. J Immunol 2002; 169(11): 6435-44.
95. Gao P, Zhou XY, Yashiro-Ohtani Y, Yang YF, Sugimoto N, Ono S, et al. The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3. J Leukoc Biol 2003; 73(2): 273-80.
96. Yang YF, Mukai T, Gao P, Yamaguchi N, Ono S, Iwaki H, et al. A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses. Eur J Immunol 2002; 32(8): 2124-32.
97. Matthys P, Hatse S, Vermeire K, Wuyts A, Bridger G, Henson GW, et al. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. J Immunol 2001; 167(8): 4686-92.
98. Girard JP, Springer TA. High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. Immunol Today 1995; 16(9): 449-57.
99. Fan L, Reilly CR, Luo Y, Dorf ME, Lo D. Cutting edge: ectopic expression of the chemokine TCA4/SLC is sufficient to trigger lymphoid neogenesis. J Immunol 2000; 164(8): 3955-9.
100. Chen SC, Vassileva G, Kinsley D, Holzmann S, Manfra D, Wiekowski MT, et al. Ectopic expression of the murine chemokines CCL21a and CCL21b induces the formation of lymph node-like structures in pancreas, but not skin, of transgenic mice. J Immunol 2002; 168(3): 1001-8.
101. Weninger W, Carlsen HS, Goodarzi M, Moazed F, Crowley MA, Baekkevold ES, et al. Naive T Cell Recruitment to Nonlymphoid Tissues: A Role for Endothelium-Expressed CC Chemokine Ligand 21 in Autoimmune Disease and Lymphoid Neogenesis. J Immunol 2003; 170(9): 4638-48.
102. Armengol MP, Cardoso-Schmidt CB, Fernandez M, Ferrer X, Pujol-Borrell R, Juan M. Chemokines determine local lymphoneogenesis and a reduction of circulating CXCR4(+) T and CCR7 B and T lymphocytes in thyroid autoimmune diseases. J Immunol 2003; 170(12): 6320-8.
103. Freyschmidt-Paul P, Hoffmann R, Levine E, Sundberg JP, Happle R, McElwee KJ. Current and potential agents for the treatment of alopecia areata. Curr Pharm Design 2001; 7(3): 213-30.
104. Orita M, Yamamoto S, Katayama N, Fujita S. Macrophage migration inhibitory factor and the discovery of tautomerase inhibitors. Curr Pharm Design 2002; 8(14): 1297-317.
105. Rajarathnam K. Designing decoys for chemokine-chemokine receptor interaction. Curr Pharm Design 2002; 8(24): 2159-69.